Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Juvenile myelomonocytic leukemia

Emi H Caywood, MD
E Anders Kolb, MD
Section Editor
Julie R Park, MD
Deputy Editor
Alan G Rosmarin, MD


Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive myeloproliferative/myelodysplastic disorder of infancy and childhood that is manifest as increased infiltration of the peripheral blood, bone marrow, and viscera by abnormal myelomonocytic cells. The vast majority of patients with JMML have somatic and/or germline mutations of genes within the RAS/MAPK signaling pathway. Allogeneic hematopoietic cell transplantation is the only curative therapy for JMML.

The clinical manifestations, diagnosis, prognosis, and treatment of JMML will be reviewed here. Chronic myelomonocytic leukemia (CMML) and chronic myeloid leukemia (CML) are discussed separately. Overviews of myelodysplastic syndromes and myeloproliferative neoplasms are discussed separately. (See "Chronic myelomonocytic leukemia" and "Clinical manifestations and diagnosis of chronic myeloid leukemia" and "Clinical manifestations and diagnosis of the myelodysplastic syndromes" and "Overview of the myeloproliferative neoplasms".)


Although much is known about the underlying molecular defects in JMML, the precise mechanisms by which these abnormalities cause this aggressive leukemia remain to be fully elucidated. The vast majority of children with JMML have somatic and/or germline mutations of genes involved in the RAS/MAPK signaling pathway. The resultant pathologic activation of signaling causes hypersensitivity of myeloid progenitor cells to the granulocyte-monocyte colony stimulating factor (GM-CSF) [1-4]. In vitro hypersensitivity of monocyte/macrophage colonies to GM-CSF long represented a diagnostic tool for JMML, and is still used as a minor diagnostic criterion for those patients without an identified underlying molecular defect. (See 'Diagnosis' below.)

Mutations in NF1, PTPN11, KRAS, NRAS, or CBL are found in more than 90 percent of patients with JMML. Alterations of JAK2, TET2, RUNX1, ASXL1, and FLT3, which are commonly associated with myeloproliferative neoplasms (MPNs) of adulthood, are rarely seen in JMML [1,5-9]. In most cases, the mutations associated with JMML are mutually exclusive within a given individual, suggesting that a mutation in any one of these genes is sufficient to activate the signaling pathway and drive the proliferation of JMML cells [2]. Whole exome sequencing has detected secondary mutations of other signaling molecules in a minority of patients, and these secondary mutations may be associated with tumor progression and worse clinical outcomes [10].

DNA hypermethylation at several target genes has been observed in JMML, and this phenomenon may contribute to treatment resistance [11,12]. Although some of the proposed targets of epigenetic silencing are involved with cell proliferation (eg, CDKN2B, RASA4), it is unknown whether these contribute to the pathogenesis of the malignant phenotype or are simply epiphenomena (ie, collateral effects) of a broader hypermethylation phenotype [13].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Apr 2017. | This topic last updated: Apr 27, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol 2011; 152:677.
  2. Caye A, Strullu M, Guidez F, et al. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet 2015; 47:1334.
  3. Emanuel PD, Bates LJ, Castleberry RP, et al. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77:925.
  4. Emanuel PD, Bates LJ, Zhu SW, et al. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Exp Hematol 1991; 19:1017.
  5. Sugimoto Y, Muramatsu H, Makishima H, et al. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Br J Haematol 2010; 150:83.
  6. Gratias EJ, Liu YL, Meleth S, et al. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia. Pediatr Blood Cancer 2005; 44:142.
  7. Muramatsu H, Makishima H, Jankowska AM, et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood 2010; 115:1969.
  8. Zecca M, Bergamaschi G, Kratz C, et al. JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia. Leukemia 2007; 21:367.
  9. Pérez B, Kosmider O, Cassinat B, et al. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br J Haematol 2010; 151:460.
  10. Sakaguchi H, Okuno Y, Muramatsu H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013; 45:937.
  11. Olk-Batz C, Poetsch AR, Nöllke P, et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood 2011; 117:4871.
  12. Batz C, Sandrock I, Niemeyer CM, Flotho C. Methylation of the PTEN gene CpG island is infrequent in juvenile myelomonocytic leukemia: Comments on "PTEN deficiency is a common defect in juvenile myelomonocytic leukemia" [Leuk. Res. 2009;33:671-677 (Epub 2008 November 17)]. Leuk Res 2009; 33:1578.
  13. Poetsch AR, Lipka DB, Witte T, et al. RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics 2014; 9:1252.
  14. Sakashita K, Matsuda K, Koike K. Diagnosis and treatment of juvenile myelomonocytic leukemia. Pediatr Int 2016; 58:681.
  15. Chang TY, Dvorak CC, Loh ML. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood 2014; 124:2487.
  16. Dong L, Yu WM, Zheng H, et al. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. Nature 2016; 539:304.
  17. Kratz CP, Rapisuwon S, Reed H, et al. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 2011; 157C:83.
  18. Niemeyer CM. RAS diseases in children. Haematologica 2014; 99:1653.
  19. Ekvall S, Wilbe M, Dahlgren J, et al. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature. BMC Med Genet 2015; 16:95.
  20. Bader-Meunier B, Tchernia G, Miélot F, et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 1997; 130:885.
  21. Side LE, Shannon KM. Myeloid disorders in infants with Noonan syndrome and a resident's "rule" recalled. J Pediatr 1997; 130:857.
  22. Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010; 42:794.
  23. Rauen KA, Schoyer L, McCormick F, et al. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A 2010; 152A:4.
  24. Matsuda K, Sakashita K, Taira C, et al. Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia. Br J Haematol 2010; 148:593.
  25. Kratz CP, Niemeyer CM, Castleberry RP, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005; 106:2183.
  26. Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009; 114:1859.
  27. SEER Data http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5393/ (Accessed on June 05, 2016).
  28. Chan RJ, Cooper T, Kratz CP, et al. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res 2009; 33:355.
  29. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia 1995; 9:1569.
  30. Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997; 89:3534.
  31. Aricò M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood 1997; 90:479.
  32. Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 2008; 140:610.
  33. Moritake H, Ikeda T, Manabe A, et al. Cytomegalovirus infection mimicking juvenile myelomonocytic leukemia showing hypersensitivity to granulocyte-macrophage colony stimulating factor. Pediatr Blood Cancer 2009; 53:1324.
  34. Lorenzana A, Lyons H, Sawaf H, et al. Human herpesvirus 6 infection mimicking juvenile myelomonocytic leukemia in an infant. J Pediatr Hematol Oncol 2002; 24:136.
  35. Hasegawa D, Bugarin C, Giordan M, et al. Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia. Blood Cancer J 2013; 3:e160.
  36. Loh ML. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010:357.
  37. Herrod HG, Dow LW, Sullivan JL. Persistent epstein-barr virus infection mimicking juvenile chronic myelogenous leukemia: immunologic and hematologic studies. Blood 1983; 61:1098.
  38. Nishio N, Takahashi Y, Tanaka M, et al. Aberrant phosphorylation of STAT5 by granulocyte-macrophage colony-stimulating factor in infant cytomegalovirus infection mimicking juvenile myelomonocytic leukemia. Leuk Res 2011; 35:1261.
  39. Puri K, Singh P, Das RR, et al. Diagnostic dilemma of JMML coexisting with CMV infection. Indian J Pediatr 2011; 78:485.
  40. Janik-Moszant A, Barć-Czarnecka M, van der Burg M, et al. Concomitant EBV-related B-cell proliferation and juvenile myelomonocytic leukemia in a 2-year-old child. Leuk Res 2008; 32:181.
  41. Pinkel D. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 1998; 91:365.
  42. Hoyoux C, Dresse MF, Forget P, et al. Osteopetrosis mimicking juvenile myelomonocytic leukemia. Pediatr Int 2014; 56:779.
  43. Yoshimi A, Kamachi Y, Imai K, et al. Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia. Pediatr Blood Cancer 2013; 60:836.
  44. Matsuda K, Shimada A, Yoshida N, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 2007; 109:5477.
  45. Matsuda K, Yoshida N, Miura S, et al. Long-term haematological improvement after non-intensive or no chemotherapy in juvenile myelomonocytic leukaemia and poor correlation with adult myelodysplasia spliceosome-related mutations. Br J Haematol 2012; 157:647.
  46. Passmore SJ, Chessells JM, Kempski H, et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003; 121:758.
  47. Yoshida N, Yagasaki H, Xu Y, et al. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Pediatr Res 2009; 65:334.
  48. Locatelli F, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005; 105:410.
  49. Bresolin S, Zecca M, Flotho C, et al. Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. J Clin Oncol 2010; 28:1919.
  50. Sakaguchi H, Muramatsu H, Okuno Y, et al. Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia. PLoS One 2015; 10:e0145394.
  51. Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. Blood 2015; 125:1083.
  52. Flotho C, Kratz CP, Bergsträsser E, et al. Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood 2008; 111:966.
  53. Pérez B, Mechinaud F, Galambrun C, et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet 2010; 47:686.
  54. Bergstraesser E, Hasle H, Rogge T, et al. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer 2007; 49:629.
  55. Cseh A, Niemeyer CM, Yoshimi A, et al. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood 2015; 125:2311.
  56. Manabe A, Okamura J, Yumura-Yagi K, et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002; 16:645.
  57. Locatelli F, Niemeyer C, Angelucci E, et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997; 15:566.
  58. Yabe M, Ohtsuka Y, Watanabe K, et al. Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan. Int J Hematol 2015; 101:184.
  59. Locatelli F, Crotta A, Ruggeri A, et al. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood 2013; 122:2135.
  60. Bertaina A, Bernardo ME, Caniglia M, et al. Cord blood transplantation in children with haematological malignancies. Best Pract Res Clin Haematol 2010; 23:189.
  61. Locatelli F. Improving cord blood transplantation in children. Br J Haematol 2009; 147:217.
  62. Diaz MA, Pérez-Martínez A, Herrero B, et al. Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts. Bone Marrow Transplant 2016; 51:1211.
  63. Yoshimi A, Niemeyer CM, Bohmer V, et al. Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. Br J Haematol 2005; 129:542.
  64. Yoshimi A, Bader P, Matthes-Martin S, et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005; 19:971.